Epic Sciences on Sept. 12 hauled in a $52 million Series E round to advance a portfolio of tests.
The round was led by Blue Ox Healthcare Partners, with participation by Deerfield Management and Varian. Existing investors, including Altos Capital Partners, Genomic Health, Inc., Domain Associates, VI Ventures, Alexandria Venture Investments, and Sabby Management, also participated in the financing.
Proceeds will go to predictive tests and analytics that can “guide clinicians and patients toward the ideal cancer drugs to prolong life and minimize spend on ineffective therapies,” according to the company.
The firm’s platform uses computer vision and machine learning to identify rare cancer cells in the blood.
By understanding how populations of cancer and immune cells change under different drug classes, Epic believes it’s positioned to predict which therapies will likely be effective.
The company plans to take its platform through “the appropriate regulatory approvals,” as well as integrate test results with electronic medical records.